Profil News

Our expert

Dr. Lars Bochmann

Director Marketing & Business Development

April 6, 2021

Reporting of study results: a challenge?

Since 2007 there is a legal obligation to report results of registered clinical studies in a timely manner. Now more than 10 years later, how is compliance with this regulation? Problematic,

March 16, 2021

Profil World - The clinical diabetes research newsletter - March 2021

Dear all, Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity. Upcoming

March 8, 2021

Profil leads the way in establishing audit trail review procedures in clinical studies using visual data analytics

Background For the last few years, one of the hottest topics in clinical research has been data integrity. An important part of ensuring data integrity - that is now mandated by the authorities - is

February 23, 2021

Free Online Seminar: Audit trail review in clinical studies using visual data analytics

Profil continues the successful series of scientific online seminars. On March 23th, 2021 at 4 PM CEST we will air our next free online seminar. The session is presented by Sascha Heckermann, Chief

February 9, 2021

Can serious games motivate teenagers with diabetes to adhere to their treatment?

Serious games are video games or digital games designed to promote educational content or behaviour changes rather than serving as pure entertainment. They could be a powerful tool to improve

January 7, 2021

Running clinical trials at Profil during pandemic times

Impact of COVID-19 on clinical trials In December 2019, China was affected by several cases of what was considered a fatal viral pneumonia (1). The numbers of affected patients were exponentially

December 17, 2020

Profil World - The clinical diabetes research newsletter - December 2020

Dear all, Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity. Profil

December 1, 2020

β3-adrenoceptor agonist Mirabegron – a candidate anti-obesity drug?

The β3‐adrenoceptor (β3-AR) was initially an attractive target for several pharmaceutical companies due to its high expression in rodent adipose tissue, where its activation resulted in decreased

November 17, 2020

Once-weekly basal insulin analogue in clinical development

Once-weekly basal insulin icodec treatment may offer more convenience in people with type 2 diabetes and may improve outcomes. Molecular and biological properties of once-weekly insulin icodec and